Predictors of asymptomatic ketonemia in outpatients with diabetic kidney disease receiving SGLT-2 inhibitors: a cross-sectional study
Veysel Baran Tomar, Taha Enes Cetin, Asil Demirezen, Omer Faruk Akcay, Ulver Derici, Galip Guz, Ozant Helvacı · 2026
Read Predictors of asymptomatic ketonemia in outpatients with diabetic kidney disease receiving SGLT-2 inhibitors: a cross-sectional study by Veysel Baran Tomar, Taha Enes Cetin, Asil Demirezen, Omer Faruk Akcay, Ulver Derici, Galip Guz, Ozant Helvacı (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13479832.txt.
Description
Veysel Baran Tomar and coauthors published a 2026 one-time study of silent ketone buildup in clinic patients with diabetic kidney disease on SGLT-2 blocker drugs. These drugs are now standard for this group, yet they nudge the body toward making ketones. Full ketone acid buildup in the blood is a known danger, while mild symptom-free ketone rise had never been carefully measured.
The study took in 211 adults in a row on empagliflozin or dapagliflozin. A finger-prick ketone meter read the main ketone body after a set fast. Math models then showed which traits on their own pointed to a high reading. Knowing who quietly runs ketones could help doctors decide who needs home checks or sick-day drug pauses to dodge a crisis.
Catalog record
| CREATOR | Veysel Baran Tomar, Taha Enes Cetin, Asil Demirezen, Omer Faruk Akcay, Ulver Derici, Galip Guz, Ozant Helvacı |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34485 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |